UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~August~~October 25, 2010 ~~(July 30, 2010)~~

Osteologix, Inc.
(Exact name of registrant as specified in its charter)


Delaware	333-112754	32-0104570
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4415 Cox RoadGlen Allen, Virginia		23060
4415 Cox Road Glen Allen, Virginia		23060
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (804) 747-6027

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 15.0102. ~~Entry~~Departure ~~Into~~of ADirectors ~~Material~~or ~~Definitive~~Certain ~~Agreement~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~Osteologix,~~On ~~Inc.~~October 5, 2010, ~~through~~Bobby ~~its~~W. ~~wholly~~Sandage ~~owned Irish subsidiary~~Jr., ~~Osteologix~~Ph.D. ~~Limited,~~resigned ~~and~~as ~~the~~a ~~Servier~~director ~~Research~~of ~~Group~~Osteologix, ~~the~~Inc. ~~leading~~(the ~~French~~“Company”) ~~independent~~effective ~~pharmaceutical~~immediately. ~~company,~~Mr. Sandage ~~entered~~previously served ~~into~~as a ~~license~~member ~~agreement~~of ~~pursuant~~the toaudit ~~which~~committee ~~Osteologix~~and ~~has granted~~the ~~Servier~~compensation ancommittee ~~exclusive~~of ~~royalty~~the Company’s ~~bearing~~board ~~license~~of todirectors. ~~develop~~Mr. Sandage ~~and~~did ~~commercialize~~not NBresign ~~S101~~because ~~(strontium malonate) to treat~~of ~~post~~any ~~menopausal~~disagreement ~~osteoporosis,~~with ~~other~~the ~~bone~~Company ~~and~~on ~~joint~~any ~~disorders~~matter ~~and~~relating ~~dental~~to ~~indications worldwide, except in~~ the ~~U.S. NB~~Company’s ~~S101~~operations, ispolicies anor ~~innovative molecule acting on both bone formation and bone resorption~~practices.

~~Under~~On October 6, 2010, the ~~terms~~Company received an action by written consent of ~~the~~stockholders ~~agreement,~~holding a ~~Osteologix~~majority ~~will~~of ~~receive~~the upCompany’s tocommon ~~€12 million~~stock insigned ~~upfront~~by Nordic Biotech K/S and Nordic ~~milestone~~Biotech ~~payments.~~Opportunity Fund K/S (the “Written Consent”) (1) ~~Additionally,~~removing ~~Osteologix~~Jeremy isCurnock ~~eligible~~Cook tofrom ~~receive~~his upposition toas ~~€30 million~~director inof ~~minimum~~the ~~royalty~~Company without ~~payments~~cause ~~creditable~~and ~~against~~(2) appointing ~~mid~~each toof Enda Kenny and David ~~low~~O’Flynn ~~single~~to ~~digit~~fill ~~royalties~~the onvacancies ~~sales~~created by the resignation of Mr. Sandage ~~Osteologix~~and ~~will~~the ~~also~~removal beof ~~eligible~~Mr. Cook, each to ~~receive~~hold ~~milestone~~such ~~payments~~office until the next annual meeting of the stockholders and ~~royalties~~until ontheir successors ~~product~~have ~~development~~been duly elected and ~~sales~~qualified in(collectively, ~~Japan~~the “Director Changes”). The ~~agreement~~Written Consent provides that the Director Changes will be effective on the date that is ~~subject~~20 calendar days immediately following the mailing of a Schedule 14C Information Statement to ~~customary~~the ~~termination~~stockholders ~~provisions~~of the Company but in no event later than November 10, 2010.

~~Safe~~The ~~Harbor~~Company ~~Statement: Statements~~intends ~~in this 8-K that are not strictly historical, including statements about potential payments and royalties~~to ~~from~~file ~~Servier~~with ~~and their impact on Osteologix’s finances,~~ the ~~potential~~U.S. ~~uses~~Securities and ~~benefits~~Exchange orCommission NB(the ~~S101,~~“SEC”) ~~Servier’s potential~~a ~~commercial~~Schedule 14C ~~launch~~Information ofStatement NBregarding ~~S101, and patent protection of NB S101 are forward-looking statements made pursuant to~~ the ~~safe-harbor~~ ~~provisions~~Director ~~of the Private Securities Litigation Reform Act of 1995~~Changes. ~~These forward-looking statements are~~After ~~subject~~the toSEC ~~risks~~review ~~and~~period ~~uncertainties~~has ~~that~~been ~~could cause actual results to differ materially from those projected or assumed in such forward-looking statements~~satisfied, ~~including,~~the ~~without~~Company ~~limitation,~~will ~~Osteologix’s~~distribute ~~obligations~~ to ~~Aditech Pharma AB, risks~~the ~~related to Servier~~Company’s ~~ability~~stockholders tosuch ~~conduct~~Schedule 14C ~~additional~~Information ~~clinical~~Statement ~~trials of NB S101, Servier’s ability~~ to ~~obtain approval~~ ~~from~~notify ~~government~~them ~~authorities~~of ~~for~~ the ~~sale~~Director ~~and~~Changes ~~distribution~~in ofaccordance ~~NB S101, Servier’s compliance~~ with ~~terms~~the ofrules ~~our agreement,~~and ~~market~~regulations ~~acceptance~~ of NBthe ~~S101 and potential success and introduction of competing products~~SEC. ~~Additional~~Pursuant ~~factors that could cause actual results~~ to ~~differ~~the ~~materially~~rules ~~are~~and ~~included~~regulations ~~under~~of the ~~heading “Risk Factors” in Part II~~SEC, ~~Item 1A of~~the ~~our Quarterly Report on Form 10-Q filed May~~Schedule ~~17,~~14C ~~2010.~~Information ~~All~~Statement ~~forward-looking~~must ~~statements~~be ~~and~~sent ~~risk~~to ~~factors~~stockholders ~~included~~at ~~in this~~least ~~document~~20 ~~are~~calendar ~~made~~days asprior ofto the earliest date ~~hereof, based~~ on ~~information~~which ~~available to us as of~~ the ~~date~~proposed ~~hereof, and we assume no~~corporate ~~obligation~~action tomay ~~update~~be ~~any forward-looking statement or risk factor~~taken. ~~You should consult the risk factors listed in our~~ ~~Annual Report on Form 10-K and from time to time in our Quarterly Reports on Form 10-Q.~~

~~Item~~Upon 8effectiveness of the Director Changes, Mr.01 Kenny ~~Other~~and ~~Events~~Mr. O’Flynn will receive the standard compensation for members of the board of directors as set forth in the Company’s definitive proxy statement on Schedule 14A filed with the SEC. The Company has not yet determined on which committee(s) of the board of directors Mr. Kenny and Mr. O’Flynn will serve upon effectiveness of the Director Changes. Mr. O’Flynn currently serves as the managing director of Osteologix Ltd., a wholly-owned subsidiary of the Company organized in Ireland.

~~On August~~ 2~~, 2010, the Company issued the press release attached hereto as Exhibit 99.1 regarding the Licensing~~ ~~Agreement.~~

~~(d) Exhibits~~SIGNATURES

~~99.1~~Pursuant ~~Press~~to ~~Release~~the requirements of ~~Osteologix,~~the Securities ~~Inc.~~Exchange ~~dated~~Act ~~July 30~~of 1934, ~~2010~~the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

~~SIGNATURES~~OSTEOLOGIX, INC.

~~Pursuant~~By: to/s/ ~~the~~Philip ~~requirements~~J. ofYoung ~~the~~Philip ~~Securities~~J. ~~Exchange~~Young ~~Act~~President ofand ~~1934,~~Chief ~~the~~Executive ~~Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.~~ Officer

~~OSTEOLOGIX~~Date: October 8, ~~INC.~~2010

Date: August 2, 2010

Filing Compare · Osteologix, Inc.